Resectable Lung Non-Small Cell Carcinoma Clinical Trial
Official title:
Proton Beam Radiation Therapy in Patients With Resected N2 Non-Small Cell Lung Cancer
This clinical trial tests proton beam radiation therapy in patients with non-small cell lung cancer who have undergone surgical resection and have lymph nodes involving the middle of the chest. Proton therapy is a type of radiation treatment that kills cancer cells while avoiding surrounding healthy tissue. Proton beam therapy is sometimes used after cancer surgery to reduce the risk of cancer recurrence (coming back). Giving proton beam radiation therapy may work better than conventional radiation treatment after surgery in patients with non-small cell lung cancer.
PRIMARY OBJECTIVE: I. To assess the safety of proton beam radiation therapy (PBRT) for resected N2 non-small cell lung cancer (NSCLC). SECONDARY OBJECTIVES: I. To measure the radiation dose to the circulating immune compartment and explore its association with clinical endpoints. II. To assess the efficacy of PBRT for resected N2 NSCLC. OUTLINE: Patients undergo radiation treatment planning and then undergo proton beam radiation therapy on study. Patients also undergo collection of blood samples. Patients are followed up for 24 months after first dose of radiotherapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03824977 -
Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery
|
||
| Not yet recruiting |
NCT06431633 -
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
|
Phase 2 | |
| Not yet recruiting |
NCT06276530 -
Impact of Surgical Approach on Adaptation of Posture-respiratory Coupling
|
N/A | |
| Recruiting |
NCT06241807 -
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
|
Phase 2 | |
| Terminated |
NCT04560686 -
Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT06349642 -
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
|